SCHEMBL661120

SCHEMBL661120

CON(C)C(=O)CN1C(=O)Cc2cc(Cl)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.42
USP2 O75604 1/20 0.41
HTT P42858 1/20 0.41
CRHR1 P34998 1/20 0.40
LMNA P02545 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
CACNA1S Q13698 3/20 0.38
NPY5R Q15761 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.37
NOTUM Q6P988 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12571561 0.80 HTT (0.62) USP2HTTLMNAMAPTMEN1
SCHEMBL29868599 0.79 KMT2A (0.47) HTTLMNATP53MAPTKDM4E
SCHEMBL661498 0.79 KMT2A (0.47) HTTLMNATP53MAPTKDM4E
SCHEMBL2009991 0.79 PTGDR2 (0.49) PTGDR2HDAC1HDAC8HDAC6CYP1A2
SCHEMBL12472048 0.78 HDAC1 (0.39) PTGDR2USP2HTTCRHR1LMNA
SCHEMBL3371437 0.78 HDAC1 (0.44) PTGDR2USP2HTTCRHR1LMNA
SCHEMBL661388 0.78 HDAC1 (0.44) PTGDR2USP2HTTCRHR1LMNA
SCHEMBL12471781 0.77 PLK1 (0.46) HTTCRHR1HDAC1HDAC8HDAC6
SCHEMBL27653941 0.75 CRHR1 (0.37) PTGDR2USP2HTTCRHR1LMNA
SCHEMBL11526516 0.74 BRD4 (0.55) CRHR1LMNAHDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP claimed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US claimed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-04-22 US disclosed
WO-2010044878-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2010-04-22 WO disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 PTGDR2 2081/4885USP2 405/4885HTT 1263/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A PTGDR2 2224/4885USP2 952/4885HTT 352/4885
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 PTGDR2 1833/4885USP2 2028/4885HTT 817/4885
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 PTGDR2 662/4885USP2 2939/4885HTT 1781/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 PTGDR2 1833/4885USP2 2028/4885HTT 817/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 PTGDR2 1833/4885USP2 2028/4885HTT 817/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 PTGDR2 2081/4885USP2 405/4885HTT 1263/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE PTGDR2 3274/4885USP2 686/4885HTT 954/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 PTGDR2 662/4885USP2 2939/4885HTT 1781/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 PTGDR2 1365/4885USP2 1905/4885HTT 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.